treatment 1 at day 12
to the vaccine dose used for the IN inoculation. Because of these results, we looked into what might have caused the high levels of humoral and CMI responses after BAd-H5HA was given to IN. To sum up, the lungs of mice in the BAdV vector group have more innate and adaptive immunity-related factors than those in the HAdV vector group. This suggests that the BAdV vaccine platform is the best way to make vaccines against new infectious diseases and cancer immunotherapy.